Yatharth Hospital & Trauma Care Services Limited (YATHARTH) fair value: what the stock is really worth
As of Oct 1, 2026: fair value of Yatharth Hospital & Trauma Care Services Limited ₹306, price ₹1,034, upside -70.4%, quality 39 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Yatharth Hospital & Trauma Care Services Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 1, 2026.
How to read this chart
38‑month range ₹312.25 – ₹1,162 · fair‑value band ₹229.73 – ₹382.93 · the ₹1,034 price screens above the ₹306.33 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 1, 2026.
Follow Yatharth Hospital & Trauma Care Services in your weekly email
Every Wednesday you see whether Yatharth Hospital & Trauma Care Services is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Yatharth Hospital & Trauma Care Services Limited, together with its subsidiaries, owns and operates super-specialty hospitals in India.
Show more
Yatharth Hospital & Trauma Care Services Limited, together with its subsidiaries, owns and operates super-specialty hospitals in India. The company offers services in the areas of medicine, cardiology, neurosciences, general surgery, nephrology and urology, pediatrics, gastroenterology, pulmonology, gynecology, orthopedics, spine and rheumatology, plastic and cosmetic surgery, ear, nose, throat, endocrinology, critical care, dermatology, nuclear medicine, and cancer and bone marrow transplant. It also provides services in the areas of GI surgery and liver transplant, robotic surgery, kidney transplant, IVF and fertility, emergency medicine, ophthalmology, dentistry, psychology and psychiatry, physiotherapy and rehabilitation, anesthesiology, radiology, pathology and laboratory medicine, nutrition and health, interventional spine and pain medicine, neurology, neurosurgery, and cardiovascular and thoracic surgery. In addition, the company sells medicines and canteen food. The company was incorporated in 2008 and is based in Noida, India.
Stock analysis
Yatharth Hospital & Trauma Care Services Limited (YATHARTH) currently trades at ₹1,034, while our model-based Fair Value estimate is ₹306.33, 70.4% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of ₹845.64 per share, and 0 of the 14 models we run sit above the ₹1,034 price.
Bear case: the Asset-Based group reads lowest at ₹123.81, and 14 of the 14 models stay below the price. Evidence for this calculation is medium.
Scenario range: ₹229.73 (bear) to ₹382.93 (bull), the price of ₹1,034 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 39/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Yatharth Hospital & Trauma Care Services Limited reported revenue of ₹12.1B in FY2026 versus ₹4.0B in FY2022, a compound +31.7%/yr. Reported net income was ₹1.8B in FY2026, compounding +41.2%/yr from FY2022.
Key figures
Market cap ₹99.6B (≈ $1.0B) · P/E ratio 54.9 · P/S ratio 7.97 · EPS (TTM) ₹18.84 · Net margin 14.5% · Return on equity 9.9% · Return on assets (EBIT) 15.1% · Operating margin 16.2%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 11% below its 52-week high and 88% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at −70%, YATHARTH screens richer than that median.
Fair Value models
Bear ₹229.73Fair Value ₹306.33Bull ₹382.93
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2026 figures (about 6 months old). Earnings retained since then (₹9.55 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.57/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+37.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+32.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+39.5%
Start year 2021 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+42.4%
’19
’20
’21
’22
’23
’24
’25
’26
What shareholders gained per year (last 5 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+38.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year+38.1%
Dividend (yield on the price)0.0%
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.21% → 17%
Compare Yatharth Hospital & Trauma Care Services Limited with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 241 stocks
Beats the industry median on 6/13 measures
A mixed picture versus its industry peers.
Valuation
Quality Score39 · Bottom 25%
Fair Value upside−70.4% · Bottom 25%
Profitability
Return on equity (TTM)9.9% · Above median
Return on assets7.2% · Top 25%
Net margin (TTM)13.2% · Top 25%
Operating margin (TTM)16.2% · Top 25%
Growth and dividend
Revenue growth52.3% · Top 25%
Dividend yield (TTM)0.0% · Bottom 25%
Balance sheet
Debt / equity0.13× · Below median
Valuation Multiplesvs Medical Care Facilities median · lower = cheaper
P/E (TTM)54.9× · Priciest 25%
P/B5.59× · Priciest 25%
P/S (TTM)7.29× · Priciest 25%
EV/EBITDA29.3× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 33
FUTURE (revenue growth)100· sector 29
PAST (return on equity)40· sector 32
HEALTH (low debt)94· sector 89
DIVIDEND (yield)0· sector 38
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Yatharth Hospital & Trauma Care Services Limited Fair Value". https://www.fairvalue-calculator.com/stock/YATHARTH
Frequently asked questions
Is Yatharth Hospital & Trauma Care Services Limited (YATHARTH) overvalued or undervalued?
As of Oct 1, 2026, our model estimates a fair value of ₹306.33 versus a price of ₹1,034, about −70% upside (overvalued).
What is the fair value of YATHARTH?
Our model-based fair value for Yatharth Hospital & Trauma Care Services Limited is ₹306.33 (as of Oct 1, 2026), built from audited fundamentals. The current price: ₹1,034.
What is the quality score of YATHARTH?
Yatharth Hospital & Trauma Care Services Limited has a Quality Score of 39/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Yatharth Hospital & Trauma Care Services Limited (YATHARTH)?
Our model-based price target is the fair value of ₹306.33 (as of Oct 1, 2026) from 14 valuation models. Cautious scenario ₹229.73, optimistic scenario ₹382.93. It is a calculation from audited fundamentals, not an analyst target.
What is the Yatharth Hospital & Trauma Care Services Limited stock forecast for 2026?
Our models put fair value at ₹306.33, about −70% upside versus a price of ₹1,034 (overvalued). Cautious scenario ₹229.73, optimistic scenario ₹382.93. The calculation is refreshed regularly with new filings.
What is the revenue of Yatharth Hospital & Trauma Care Services Limited (YATHARTH)?
Yatharth Hospital & Trauma Care Services Limited reported trailing-twelve-month revenue of about ₹13.7B (latest available figure, as of Oct 1, 2026).
What is the intrinsic value of Yatharth Hospital & Trauma Care Services Limited (YATHARTH)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Yatharth Hospital & Trauma Care Services Limited it is ₹306.33 per share (as of Oct 1, 2026), against a price of ₹1,034. It is the blended result of 14 valuation models (cash flow, earnings, asset, dividend).
Is Yatharth Hospital & Trauma Care Services Limited stock overvalued or undervalued in 2026?
As of Oct 1, 2026, YATHARTH trades above its calculated fair value: price ₹1,034, fair value ₹306.33, a gap of about −70% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of YATHARTH?
No. The price is what the market pays today (₹1,034); the fair value is what the company's own numbers justify (₹306.33). For Yatharth Hospital & Trauma Care Services Limited the two are ₹727.37 per share apart. That gap is exactly why we show both numbers side by side.
How much is Yatharth Hospital & Trauma Care Services Limited worth?
The market values Yatharth Hospital & Trauma Care Services Limited at about ₹99.6B (market capitalisation, as of Oct 1, 2026). Per share that is ₹1,034; our models calculate a fair value of ₹306.33 per share.
What do the bullish and bearish scenarios say about YATHARTH?
Our models span a range for Yatharth Hospital & Trauma Care Services Limited: cautious scenario ₹229.73, base ₹306.33, optimistic ₹382.93 per share (as of Oct 1, 2026, price ₹1,034). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of YATHARTH?
Yatharth Hospital & Trauma Care Services Limited trades at a price-to-earnings ratio of 54.9 (as of Oct 1, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹306.33 is built from several models across several years. Other multiples: P/B 5.6, P/S 7.3, EV/EBITDA 29.3.
How solid is the balance sheet of Yatharth Hospital & Trauma Care Services Limited (YATHARTH)?
Balance-sheet figures for Yatharth Hospital & Trauma Care Services Limited (as of Oct 1, 2026): return on equity 9.9%, debt of 0.13 per unit of equity. They feed the Quality Score of 39/100, which measures business quality independently of the share price.
How far is YATHARTH from its 52-week high?
Yatharth Hospital & Trauma Care Services Limited trades at ₹1,034, about 11% below its 52-week high of ₹1,162 and 88% above the low of ₹550.80 (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of ₹306.33 is for.
Which stocks are comparable to Yatharth Hospital & Trauma Care Services Limited?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Dr. Sulaiman Al Habib Medical Services Group, Tenet Healthcare Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Yatharth Hospital & Trauma Care Services Limited stock attractive at the current price?
The data as of Oct 1, 2026: price ₹1,034, calculated fair value ₹306.33 (−70%), Quality Score 39/100, from 14 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of YATHARTH calculated?
We run Yatharth Hospital & Trauma Care Services Limited through 14 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹306.33, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Yatharth Hospital & Trauma Care Services Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Yatharth Hospital & Trauma Care Services Limited (YATHARTH)?
The closing price on Oct 1, 2026 was ₹1,034. Our model-based fair value is ₹306.33, about −70% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Yatharth Hospital & Trauma Care Services Limited right now?
The price sits above even our optimistic bull case (₹382.93). The favourable scenario is already priced in. Weak quality (39/100) and above fair value at the same time, the margin of safety is missing on both counts.
Key figures of Yatharth Hospital & Trauma Care Services Limited
How large is the market capitalisation of Yatharth Hospital & Trauma Care Services Limited (YATHARTH)?
The market capitalisation of Yatharth Hospital & Trauma Care Services Limited is ₹99.6B (≈ $1.0B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Yatharth Hospital & Trauma Care Services Limited (YATHARTH)?
The price-to-sales ratio of Yatharth Hospital & Trauma Care Services Limited is 7.97 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Yatharth Hospital & Trauma Care Services Limited (YATHARTH)?
Earnings per share at Yatharth Hospital & Trauma Care Services Limited are ₹18.84 (price ÷ EPS = P/E 54.9). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Yatharth Hospital & Trauma Care Services Limited (YATHARTH)?
The net margin of Yatharth Hospital & Trauma Care Services Limited is 14.5% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Yatharth Hospital & Trauma Care Services Limited (YATHARTH)?
The return on equity (ROE) of Yatharth Hospital & Trauma Care Services Limited is 9.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Yatharth Hospital & Trauma Care Services Limited (YATHARTH)?
On an EBIT basis the return on assets of Yatharth Hospital & Trauma Care Services Limited is 15.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Yatharth Hospital & Trauma Care Services Limited (YATHARTH)?
The operating margin of Yatharth Hospital & Trauma Care Services Limited is 16.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Yatharth Hospital & Trauma Care Services Limited (YATHARTH)?
Revenue at Yatharth Hospital & Trauma Care Services Limited is growing +52.3% versus a year earlier (3y avg +32.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Yatharth Hospital & Trauma Care Services Limited (YATHARTH)?
Earnings per share at Yatharth Hospital & Trauma Care Services Limited are growing +11.9% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Yatharth Hospital & Trauma Care Services Limited (YATHARTH) generate?
The free cash flow of Yatharth Hospital & Trauma Care Services Limited is −₹957M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Yatharth Hospital & Trauma Care Services Limited (YATHARTH) carry?
The net debt of Yatharth Hospital & Trauma Care Services Limited is ₹7.3M (fiscal year 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Yatharth Hospital & Trauma Care Services Limited in the live analysis
One click puts Yatharth Hospital & Trauma Care Services Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
